Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

In most countries, testosterone therapy is prescribed off-label such that women are using either testosterone formulations approved for men with dose modification, or compounded therapies. Current research into testosterone physiology and clinical effects should mainly focus on measuring total testosterone as the main biomarker rather than "free" testosterone, as evidence that "free" testosterone is the biologically active testosterone fraction is lacking[9] (Expert Opinion). Studies of non-oral testosterone therapies (percutaneous and injectable), I in doses that approximate physiological testosterone concentrations for premenopausal women i , have shown no significant adverse effects on lipid profiles over the short term (Level I, Grade A). Should a trial of testosterone therapy be given for HSDD, a baseline total testosterone concentration should be measured before commencement, with a repeat level 3-6 weeks after treatment initiation (Level IIA, Grade C). [Extracted from the article]